Details For Selected Brain Tumor Treatment

Sponsored By

Please Click On The Above Banner For More Details

Last updated refers to the date when our listing for each treatment was last updated.
ID is our internal ID - starting with VT.
Min Karnofsky is a general guide to how well you have to function to use this treatment
For trials that also have a NCT number, you can click that number to pop up the listing from the clinicaltrials.gov website.

Back to New Treatments List



		Treatment Name:		Phase I Study of Immunization With Autologous Tumor Lysate-Pulsed Dendritic Cells in Patients With Malignant Gliomas (Vaccine Therapy in Treating Patients With Malignant Glioma)

		Keywords:		Vaccine Therapy

		Phase:		Phase 1

		Treatment ID#s:		VT1131 NCT00068510

		Age Group:		Adults Only

		Min Karnofsky Score:		60: Requires occasional assistance but is able to care for most of own needs

		Conditions:		Newly Diagnosed: Y Recurrent: Y Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Allowed Newly diagnosed or recurrent malignant glioma and surgically accessible tumor for which resection is indicated

		Last Updated:		03/02/2008

		Tumor Types:		Anaplastic Astrocytoma Glioblastoma Multiforme Gliosarcoma Oligodendroglioma High Grade


		Comments:		Patients undergo leukapheresis for the collection of peripheral blood mononuclear cells (PBMC). Autologous dendritic cells (DC) are prepared from autologous PBMC exposed to sargramostim (GM-CSF) and interleukin-4 and pulsed with autologous tumor lysate. Patients receive autologous tumor lysate-pulsed DC intradermally on days 0, 14, and 28 in the absence of unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of autologous tumor lysate-pulsed DC until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed every 2 months for 1 year.

		Treatment Type:		Immunological, Biological or Targeted Therapy.

		Contact:		UCLA Medical Center Linda M. Liau, MD, PhD Co-director, Brain Tumor Program David Geffen School of Medicine at UCLA 10833 Le Conte Avenue, CHS 74-145 Los Angeles, CA 90095 Phone:310-267-2621 Fax: 310-825-7245 Click here to send an email Website: neurosurgery.ucla.edu/

Translate this pageMicrosoftÂ® Translator

Copyright (c) 1993 - 2009 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740

Website Design By